In VivoThe US Food and Drug Administration’s complete response letter for Replimune ’s RP1 appears to point the company in a different direction than its previous interactions with the agency, providing fur
Pink SheetThe US Food and Drug Administration’s complete response letter for Replimune ’s RP1 appears to point the company in a different direction than its previous interactions with the agency, providing fur
Pink SheetThe US Food and Drug Administration’s approval decisions for novel agents will come from different divisions in the second half of 2025, compared to the first half, the Pink Sheet ’s US FDA Performan
ScripStock market turmoil due to macroeconomic uncertainty and biopharmaceutical industry-specific concerns have made it more difficult for publicly traded drug developers to pursue follow-on public offeri